Skip to main content

Table 1 Clinico-pathological characteristics and TRAIL-R1 expression of patients with colorectal carcinoma

From: Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations

   

High TRAIL-R1

Low TRAIL-R1

p value

 

N

%

N

%

N

%

 

Total Number of Cases

387

 

331

85.5

56

14.5

 

Age

       

   < = 50 years

126

32.6

110

87.3

16

12.7

0.4870

   > 50 years

261

67.4

221

84.7

40

15.3

 

Gender

       

   Male

193

49.9

167

86.5

26

13.5

0.5773

   Female

194

50.1

164

84.5

30

15.5

 

Tumour Site

       

   Left colon

324

83.7

276

85.2

48

14.8

0.6576

   Right colon

63

16.3

55

87.3

8

12.7

 

Histological Type

       

   Adenocarcinoma

334

86.3

291

87.1

43

12.9

0.0355

   Mucinous Carcinoma

53

13.7

40

75.5

13

24.5

 

Tumour Stage

       

   I

55

15.0

53

96.4

2

3.6

0.0251

   II

126

34.2

105

83.3

21

16.7

 

   III

141

38.3

121

85.8

20

14.2

 

   IV

46

12.5

36

78.3

10

21.7

 

Differentiation

       

   Well

33

8.5

30

90.9

3

9.1

0.0887

   Moderate

284

73.4

247

87.0

37

13.0

 

   Poor

70

18.1

54

77.1

16

22.9

 

KRAS Mutation

       

   Present

75

28.3

67

89.3

8

10.7

0.7407

   Absent

190

71.7

167

87.9

23

12.1

 

K-RAS 2A

       

   High expression

155

46.7

150

96.8

5

3.2

< 0.0001

   Low expression

177

53.3

142

80.2

35

19.8

 

Cleaved-Caspase 3

       

   High expression

172

49.9

160

93.0

12

7.0

0.0011

   Low expression

173

50.1

141

81.5

32

18.5

 

P27 (Nuc)

       

   High expression

139

38.4

130

93.5

9

6.5

0.0024

   Low expression

223

61.6

185

83.0

38

17.0

 

MSI-Molecular

       

   MSI-H

67

18.7

56

83.6

11

16.4

0.4731

   MSI-S/L

292

81.3

254

87.0

38

13.0

 

Overall Survival

       

   5 Years

   

68.1

 

53.9

0.0124